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Stroke in China (TIMS-China) study. Efficacy data were derived from a pooled analy-
sis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Costs and quality-adjusted life-
years (QALYs) were compared both in short term (2 years) and in long term (30 years). 
One-way and probabilistic sensitivity analyses were performed to test the robust-
ness of the results. Results: Comparing to no tPA treatment, tPA treatment within 
4.5 hours has a gain of 0.101 QALYs at an additional cost of CNY 9,520 (US$ 1,460), 
yielding an incremental cost-effectiveness ratio (ICER) of CNY 94,300 (US$ 14,500) 
per QALY gained after 2 years, and a lifetime gain of 0.422 QALYs at an additional 
cost of CNY 6,530 (US$ 1,000), yielding an ICER of CNY 15,500 (US$ 2,380) per QALY 
gained. Probabilistic sensitivity analysis shows that tPA treatment is cost-effective 
in 98.7% of the simulations at a willingness-to-pay threshold of CNY 105,000 (US$ 
16,200) per QALY. ConClusions: Intravenous tPA treatment within 4.5 hours is 
highly cost-effective for acute ischemic stroke in China setting.
QA4
Cost-Utility of BevACizUmAB with PC Regimen in non-smAll Cell lUng 
CAnCeR tReAtment
Nguyen T.T.T., Tran T.T.H. 
University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam
objeCtives: Lung cancer, especially non-small cell lung cancer (NSCLC), is one 
of the most leading causes of mortality not only in the world but also in Vietnam. 
Bevacizumab – a targeted therapy agent- has been recommended to use in combina-
tion with chemotherapy as the first-line treatment of advanced NSCLC. However, the 
high cost of bevacizumab may reduce the availability of bevacizumab, especially in 
Vietnam. Therefore, this analysis was conducted to analyze the cost-effectiveness 
of bevacizumab in the combination with paclitaxel and carboplatin (BCP) versus 
paclitaxel and carboplatin regimen (PC) in Vietnamese setting. Methods: A Markov 
model has been developed with 3 stages (stable, progressive and death). The model 
has a cycle length of 1 year with the life-time horizon. The population of 1000 
patients was included in the  model. The transition rates have been retrieved from 
randomized clinical trials, the prices of drugs and medical services have been aver-
aged from the price-lists of some major hospitals in Vietnam in 2013. The sensitiv-
ity analysis has been conducted. Results: The cost of BCP and PC regimen for 
NSCLC treatment accounts for 4,691,452,387 VND and 1,792,656,298 VND with the 
QALY of 7.88 and 5.62, respectively. The CER of BCP regimen for NCSLC treatment 
accounts for 595,533,261 VND, which is around 2 times higher than that of PC regi-
men. The ICER of BCP regimen versus PC regimen accounts for around 1.3 billion 
VND, which is about 17 times higher than the willingness-to-pay of Vietnam (74 
million VND). One-way sensitive analysis showed bevacizumab price as the most 
affecting factor on its cost-effectiveness. ConClusions: Due to the high cost of 
drug, the combination of bevacizumab in the PC regimen in treatment of NSCLC 
is considered not cost-effective in Vietnam. To enhance the cost-effectiveness of 
bevacizumab, supporting policies from manufacturer, health care providers and 
government should be established.
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objeCtives:  To evaluate physician’s knowledge and adherence to asthma guideline 
adherence (GINA 2011) at emergency department of Hospital Pulau Pinang, Malaysia 
and to calculate cost of adhered and non-adhered prescriptions. Methods: 
A cross-sectional survey was conducted to evaluate knowledge of GINA, 2011 asthma 
guideline at emergency department of Hospital Pulau Pinang, Malaysia. A total of 
810 patient prescriptions of 27 doctors (30 prescriptions per doctor) were viewed 
to asses doctor’s guideline adherence. Patients’ prescriptions were categorised in 
terms of asthma severity as mild, moderate and severe. Prescriptions were labelled 
as adhered or non-adhered in terms of doctor treatment according to patient 
asthma severity as recommended by CPG (GINA 2011). Cost of adhered and non-
adhered was calculated according to asthma severity. Results: Twenty two (81.5%) 
doctor’s had adequate GINA, 2011 asthma guideline knowledge (Mean 16.7, SD ± 
1.5). Six hundred and twenty eight (77.5%) patients received guideline (GINA 2011) 
adhered pharmacotherapy. Six hundred and seventy eight (83.7%) patients asthma 
were classified as mild asthma, 128 (15.8%) patients were classified as moderate 
asthma and 4 (0.5%) patients were classified as severe asthma. Pearson correlation 
indicated no statistical significant association between asthma guideline adher-
ence and asthma guideline knowledge score (p= 0.27). Univariate analysis indicate 
that patients with age group 25-35 years and with hypertension as co-morbidity 
received significantly better pharmacotherapy (p= 0.04, p= 0.03 respectively). Total 
cost of 628 adhered prescriptions was RM 5792.87 whereas cost of 182 non-adhered 
prescriptions was RM 1759.09. Cost of single mild asthma adhered prescription 
(RM 9.18) was less as compared to non adhered mild asthma prescription (RM 
10.39). ConClusions: Emergency doctor’s had adequate GINA, 2011 asthma guide-
line knowledge. Majority of patients received GINA, 2011 asthma guideline adhered 
pharmacotherapy. Cost effective medication can significantly reduce socioeconomic 
burden related to asthma.
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the usual clinic, medicines availability at the clinic in the community. Results: 
The average immunization propensity is 0.69 (7,668 of 11,114) with a mean value of 
0.57 for flu vaccine propensity. The upward trend over time in household income 
and percentage of residents in urban area indicate the rapid economic development 
and the urbanization in China from 2000 to 2006. Logit, probit, and longitudinal 
linear random effects regression analyses showed that maternal education level 
positively affects the immunization propensity for children aged ≤ 6 (p< 0.01) and for 
children aged 7-18 (p< 0.1). Other factor, such as the medical insurance, whether the 
individual resides in urban area and the needed medicines availability at the clinic, 
also had a significant impact on the immunization propensity for children and 
adolescents (p< 0.05). ConClusions: Maternal education positively affects chil-
dren’s immunization propensity, particularly for those children below 6 years of age.
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objeCtives: The purpose of this study was to compare the performance of 
the EuroQol 5-dimension (EQ-5D-5L) and the Short Form 6-dimension (SF-6D) 
instruments in assessing Asian patients with end-stage renal disease (ESRD) in 
Singapore. Methods: In a cross-sectional study, we interviewed ESRD patients 
who were dialyzed or followed up at the National University Hospital using a battery 
of questionnaires including the EQ-5D-5L, the kidney disease quality of life instru-
ment (KDQOL-36), and questions assessing dialysis history and socio-demographic 
characteristics. We reviewed patients’ medical records for their clinical information. 
We assessed the construct validity of the EQ-5D-5L and SF-6D index scores and 
compared their ability to distinguish between patients in differing health status 
and the magnitude of between-group difference they quantified. Results: One 
hundred and fifty ESRD patients on dialysis (mean age: 60.1 years; female: 48.7%) 
participated in the study. Both EQ-5D-5L and SF-6D demonstrated good known-
groups construct validity; the EQ-5D-5L was more sensitive to differences in clinical 
outcomes and the SF-6D was more sensitive to differences in KDQOL scales. The 
intraclass correlation coefficient between the measures was 0.36. The differences 
in (both actual and derived) EQ-5D index score for patients in better and worse 
health status were greater than those in SF-6D index score. ConClusions: Both 
EQ-5D-5L and SF-6D are valid instruments for assessing ESRD patients. However, 
the two preference-based health index scores cannot be used interchangeably and 
it appears that EQ-5D-5L would lead to more favorable cost-effectiveness results 
than SF-6D if they are used in economic evaluations of interventions for ESRD.
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objeCtives: HTA in Taiwan was established in December 2007 to inform decision 
making on drug approvals and reimbursement prices. Drug categories were estab-
lished based on the therapeutic value and the innovative nature of new drugs, and 
various pricing structures were adopted. Price adjustments based on demonstra-
tive improvements in clinical efficacy and safety are also able to be applied. These 
adjustments can take into account clinical and pharmacoeconomic data specifically 
relevant to Taiwan. The aim of this study was to investigate the reimbursements of 
new health technologies assessed by the NIHTA with respect to drug categorisation, 
pricing structures and applied price adjustments. Methods: NIHTA assessment 
reports from 2011 to February 2014 were reviewed, and approval and pricing deci-
sions by the NHIA were evaluated. Results: Of the 52 assessments included in this 
analysis, 37 were approved for use on the National Health Insurance (NHI) in Taiwan. 
Of these, 57% were determined as having a comparable therapeutic value to the 
current best competitor, 38% were deemed to show moderate improvements and 
5% were considered breakthrough innovations. In most instances (73%), drugs were 
priced based on existing therapies. Of the approved health technologies, 9 (24%) were 
eligible for additional price adjustments. These were spread across multiple disease 
areas and reflected improved clinical and safety outcomes, dosing convenience and 
the availability of local clinical and economic data. The incidence of price adjust-
ments has increased in recent years, which is particularly evident with respect to high 
quality pharmacoeconomic data. ConClusions: The majority of drugs approved by 
the NHIA offer similar clinical benefit to current competitors and are priced based 
on existing therapies. Alternative methods involved calculating drug prices based 
on international reference countries, although manufacturers seem to be increas-
ingly seeking available price adjustments to achieve a higher price for their product.
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objeCtives: Previous economic studies conducted in developed countries showed 
intravenous tissue-type plasminogen activator (tPA) is cost-effective for acute 
ischemic stroke. This study aims to determine the cost-effectiveness of tPA treat-
ment in China setting. Methods: A combination of a decision tree and a Markov 
model was developed to determine the cost-effectiveness of tPA treatment versus 
no tPA treatment within 4.5 hours after stroke onset. Outcomes and costs data 
were derived from the Thrombolysis Implementation and Monitor of acute ischemic 
